| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/26/2009 | US7538132 aryl-isoxazole-4-carbonyl-pyrrole-2-carboxylic acid amide derivatives; cognitive disorders like Alzheimer's disease; high affinity and selectivity for GABA A alpha 5 receptors; 4-[3-(4-Chloro-phenyl)-5-methyl-isoxazole-4-carbonyl]-1H-pyrrole-2-carboxylic acid prop-2-ynylamide |
| 05/26/2009 | US7538131 To modulate and control lipid and/or carbohydrate metabolism; atherosclerosis; acetic acid derivatives with cyclohexylmethoxy substituents; 2-[(1R,3S)-3-(2-Biphenyl-4-yl-5-methyloxazol-4-ylmethoxymethyl)cyclohexylmethoxy]-2-methylpropionic acid |
| 05/26/2009 | US7538130 Oxazole spiro derivative; easier, less expensive manufacture; incorporated in a coating composition for topcoat, clearcoat layers; against the effects of oxygen and light |
| 05/26/2009 | US7538129 Diazonamide A analog |
| 05/26/2009 | US7538128 Prophylaxis of diabetes; (1SR,3RS)-3-{2-[(2S)-2-Cyanopyrrolidin-1-yl]-2-oxoethylamino}cyclopentane-1-carboxamide; non-insulin dependent diabetes mellitus, impaired glucose homeostasis, impaired glucose tolerance, infertility, polycystic ovary syndrome |
| 05/26/2009 | US7538127 phenethanolamine derivatives like 1-(4-amino-3,5-dichlorophenyl)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]ethanol; respiratory diseases like bronchial asthma; selective stimulant of beta 2-adrenoreceptors; reductive amination; alkylation |
| 05/26/2009 | US7538126 Crystallization in solvent dimethyl formamide; x-ray powder diffraction pattern; cyclooxygenase-2 enzyme inhibitor useful for the treatment of arthritis and pain |
| 05/26/2009 | US7538125 Pioglitazone insulin sensitivity enhancer with the antidiabetic glimepiride; difference in mechanism of action avoids adverse reactions over long term use; oral dosage tablet; lactose excipient, hydroxypropylcellulose binder, magnesium stearate lubricant, calcium carbonate disintegrator; diabetes |
| 05/26/2009 | US7538124 N-(p-(2-alpha-carboxybenzylamino)ethylamino)phenyl)p-(p-trifluoromethylphenyl)benzamide; hyperlipidemia; antiobesity and anti-type II diabetic agents; Microsomal triglyceride transfer protein inhibitors |
| 05/26/2009 | US7538123 Indole derivative having piperidine ring |
| 05/26/2009 | US7538122 Modulators of CCR5(chemokine) receptors; lymphadenopathy associated and human T-cell leukemia/lymphoma viruses; AIDS infections; autoimmune diseases; antiinflammatory agents; derivatives of 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one |
| 05/26/2009 | US7538121 Vanilloid receptor modulators |
| 05/26/2009 | US7538120 e.g. 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic, antiinflammatory agent; rheumatoid arthritis |
| 05/26/2009 | US7538119 Metabolically resistant 41-[13C]methoxyl rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (41-[13C]methoxyl CCI-779); study pharmacokinetics; Rapamycin 31-O-trimethyl silyl ether, 42-ester with 2,2,5-trimethyl[1,3-dioxane]-5-carboxylic acid; treat cancers |
| 05/26/2009 | US7538118 6-aminomorphinane derivatives, method for production and use thereof |
| 05/26/2009 | US7538117 Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds |
| 05/26/2009 | US7538116 Administer gepirone as short-term or long-term therapy for female, male hypoactive sexual desire disorder, orgasmic disorder, sexual arousal disorder, depression, anxiety, panic disorder, drug abuse |
| 05/26/2009 | US7538115 Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| 05/26/2009 | US7538114 Glycine transporter-1 inhibitors |
| 05/26/2009 | US7538113 6-{4-[2-(4-tert-butyl-phenyl)-1H-imidazo[4,5-c]pyridin-4-yl]-piperazin-1-ylmethyl}quinoxaline; controls biosynthesis and release of sex steroids in the gonads; contraceptive; anticarcinogenic agent; prostate, uterine, breast, ovarian cancer, endometriosis, uterine fibroids, primary hirsutism |
| 05/26/2009 | US7538112 hydroxy-substituted pyrazinopyrrolopyridazine dione compounds; viricide; infection by HIV, AIDS; with other HIV/AIDS antivirals, immunomodulators, antibiotics or vaccines; 2-(2-fluorobenzyl)-10-hydroxy-4,8-dimethyl-7,8-dihydropyrazino[1',2':1,5]-pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-dione |
| 05/26/2009 | US7538111 N(2-hydroxyethyl)-4-methoxy-N,2,6-trimethylbenzene- sulphonamide; analgesic, antiinflammatory agent; hyperalgesia and major algesia connected with other pathological conditions such as cancer |
| 05/26/2009 | US7538110 e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction |
| 05/26/2009 | US7538109 Quinoxalin-3-one derivatives as orexin receptor antagonists |
| 05/26/2009 | US7538108 N4-(2,2-dimethyl-4-[(di-tert-butyl phosphonoxy)methyl]-3-oxo-5-pyrido [1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; Syk tyrosine kinase inhibitor; collagen-induced platelet activation inhibitor; anitinflammatory agent; autoimmune diseases; bioavailability |
| 05/26/2009 | US7538107 Oxazinan-2-one derivatives useful as PR modulators |
| 05/26/2009 | US7538106 Application of 2-cyano-10- (2-methyl-3- (methylamino)- propyl) phenothiazine or a pharmaceutically acceptable salt as medicament |
| 05/26/2009 | US7538105 Anti-infective agents |
| 05/26/2009 | US7538103 Compounds for the treatment of hepatitis C |
| 05/26/2009 | US7538102 Compounds for the treatment of Hepatitis C |
| 05/26/2009 | US7538101 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives |
| 05/26/2009 | US7538100 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations |
| 05/26/2009 | US7538099 Antiprogestin method and kit for reducing side effects associated with low dosage HRT, oral contraception and regulating menses |
| 05/26/2009 | US7538098 19-nor-vitamin D analogs with 1,2 or 3,2 heterocyclic ring |
| 05/26/2009 | US7538097 Inhibition of antigen presentation with poorly catabolized polymers |
| 05/26/2009 | US7538096 Treatment and prevention of abnormal cellular proliferation |
| 05/26/2009 | US7538095 Genetic inhibition by double-stranded RNA |
| 05/26/2009 | US7538094 Mixing ribavirin with excipient; pelletization; coating with material that reduces dissolution rate in water; sustained release, free-flowing |
| 05/26/2009 | US7538093 Compositions and methods for therapeutic use |
| 05/26/2009 | US7538092 Oligosaccharides linked by amide, imine,ether, ester, carbonate, carbamate, urea, thioester bond to active agent produce hydrophilicity; easily produced with homogeneity, predictable, desirable pharmacokinetic profile, enhanced biocompatibility |
| 05/26/2009 | US7538091 D-retro-inverso amino acid sequence transporter peptide conjugated to nucleic acid biological effector; translocation across the membrane of pancreatic B-cells |
| 05/26/2009 | US7538083 Compositions and methods for the potentiation of immune responses against target antigens |
| 05/26/2009 | US7538082 Methods and compositions for treating or preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Trefoil peptides are administered in effective concentrations either alone or in combination with |
| 05/26/2009 | US7537924 Modified herpes simplex viral particle for targeting and destroying tumor cells |
| 05/26/2009 | US7537908 Using concentration of high mobility group 1 (HMG1) protein as evaluative tool in detection of infection and acute respiratory distress syndrome; treating obesity with high mobility group antagonist |
| 05/26/2009 | US7537906 inhibition of Akt activity or inhibition of the survival signalling pathway in which Akt is involved in the cells, akt is a kinase |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | US7537785 Composition for treating vascular diseases characterized by nitric oxide insufficiency |
| 05/26/2009 | US7537774 a mixture of catechol, croconic acid and/or sulfites, tetrahydroxyquinone and/or sulfites and acetogenins, in the form of a tablet, a capsule, a liquids, transdermal patches and gels, used for the treatment of colon cancer, autoimmune disease and viral diseases |
| 05/26/2009 | US7537759 Modulating angiogenesis |
| 05/26/2009 | US7537757 Administering an antibody that specifically binds to EMAP(endothelial monocyte-activating polypeptides II) to the subject which needs inhibition of EMAP activity in an amount effective to stimulate vascular growth in cardiac muscle |
| 05/26/2009 | US7537756 Using nestin-positive pancreatic stem cell to generate insulin producing beta cells; tissue engineering and repair; regenerative medicine |
| 05/26/2009 | US7537754 Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means |
| 05/26/2009 | US7537752 Mixture of chelate compound and active material in vehicle |
| 05/26/2009 | US7537009 heating a substrate coated with formulation containing a drug ( e.g. antibiotics, antidepressants, antihistamines etc.) for a period of time, to form a vapor in less than 500 milliseconds, allowing the vapor to cool; absence of excipients |
| 05/26/2009 | CA2562938C Peg-functional nucleic acid conjugate |
| 05/26/2009 | CA2541498C Controlled release delivery system for nasal applications |
| 05/26/2009 | CA2533685C Nitrogen-containing fused heterocyclic carboxylic acid compounds |
| 05/26/2009 | CA2527274C Mixed zeaxanthin ester concentrate and uses thereof |
| 05/26/2009 | CA2497857C Novel p-selectin ligand protein |
| 05/26/2009 | CA2474373C N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykinin antagonists |
| 05/26/2009 | CA2465386C Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like |
| 05/26/2009 | CA2464223C Quarternary ammonium compounds and their use as antimuscarinic agents |
| 05/26/2009 | CA2463264C 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists |
| 05/26/2009 | CA2459432C Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 05/26/2009 | CA2455042C Method of reducing hair growth by applying alpha-difluoromethylornithine |
| 05/26/2009 | CA2454675C 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
| 05/26/2009 | CA2445478C Retinol derivatives potentiation of active substances by micellar preparation |
| 05/26/2009 | CA2441441C Combination of a taxane and a cyclin-dependent kinase inhibitor |
| 05/26/2009 | CA2436668C Novel succinate salt of o-desmethyl-venlafaxine |
| 05/26/2009 | CA2436537C Pharmaceutical compositions comprising tiotropium salts and antihistamines |
| 05/26/2009 | CA2429020C Use of cci-779 as an antineoplastic agent |
| 05/26/2009 | CA2411754C 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents |
| 05/26/2009 | CA2403630C Methods for inhibiting angiogenesis and tumor growth |
| 05/26/2009 | CA2399870C Topically applied clotting material |
| 05/26/2009 | CA2393821C Substituted imidazole neuropeptide y y5 receptor antagonists |
| 05/26/2009 | CA2387201C Tetrahydroquinoline derivatives |
| 05/26/2009 | CA2384504C Use of retigabin for treating neuropathic pain |
| 05/26/2009 | CA2376949C Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| 05/26/2009 | CA2367017C Inhibitors of impdh enzyme |
| 05/26/2009 | CA2355077C Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 05/26/2009 | CA2354774C Farnesyl protein transferase inhibitors |
| 05/26/2009 | CA2345100C Optimized use of 6-mercaptopurine drug in the treatment of immune-mediated gastrointestinal disorders |
| 05/26/2009 | CA2344058C Diaminopropionic acid derivatives |
| 05/26/2009 | CA2342211C Antibiotic compositions for treatment of the eye, ear and nose |
| 05/26/2009 | CA2340701C Oxindole derivatives as growth hormone releasers |
| 05/26/2009 | CA2339495C Phospholipids with unsaturated alkyl and acyl chains |
| 05/26/2009 | CA2337225C Novel antibacterial compounds |
| 05/26/2009 | CA2337041C Aminomethylcarboxylic acid derivatives |
| 05/26/2009 | CA2334773C Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use |
| 05/26/2009 | CA2298523C Therapeutic process for inhibiting nf-.kappa.b |
| 05/26/2009 | CA2295512C Prostaglandin product |
| 05/26/2009 | CA2279498C The use of levobupivacaine in paediatric surgery |
| 05/26/2009 | CA2254420C Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 05/26/2009 | CA2242879C Method for treating sexual dysfunctions |
| 05/26/2009 | CA2230492C Human growth hormone variants |
| 05/26/2009 | CA2226331C Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(substituted)hydrazines |
| 05/26/2009 | CA2225903C Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use |
| 05/26/2009 | CA2216653C 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity |
| 05/26/2009 | CA2185893C Multilayered controlled release pharmaceutical dosage form |